Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

NCT02134015 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02134015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02134015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2014
Completion date
November 11, 2016
Enrollment
145 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell lung cancer